Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients
Soluble suppression of tumorigenesis-2 (sST2) is an emerging biomarker for sepsis as well as for heart failure. We investigated the prognostic utility of sST2 for predicting clinical outcomes in hospitalized coronavirus disease 2019 (COVID-19) patients. In a total of 52 hospitalized COVID-19 patient...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/2/259 |
| _version_ | 1797443849567600640 |
|---|---|
| author | Mikyoung Park Mina Hur Hanah Kim Chae Hoon Lee Jong Ho Lee Hyung Woo Kim Minjeong Nam Seungho Lee |
| author_facet | Mikyoung Park Mina Hur Hanah Kim Chae Hoon Lee Jong Ho Lee Hyung Woo Kim Minjeong Nam Seungho Lee |
| author_sort | Mikyoung Park |
| collection | DOAJ |
| description | Soluble suppression of tumorigenesis-2 (sST2) is an emerging biomarker for sepsis as well as for heart failure. We investigated the prognostic utility of sST2 for predicting clinical outcomes in hospitalized coronavirus disease 2019 (COVID-19) patients. In a total of 52 hospitalized COVID-19 patients, sST2 levels were measured using the ichroma ST2 assay (Boditech Med Inc., Chuncheon-si, Gang-won-do, Republic of Korea). Clinical outcomes included intensive care unit (ICU) admission, ventilator use, extracorporeal membrane oxygenation (ECMO) use, and 30-day mortality. sST2 was analyzed according to clinical outcomes. sST2, sequential organ failure assessment (SOFA) score, critical disease, and 4C mortality score were compared using the receiver operating characteristic (ROC) curve and Kaplan–Meier methods for clinical outcomes. The sST2 level differed significantly according to ICU admission, ventilator use, ECMO use, and 30-day mortality (all <i>p</i> < 0.05). On ROC curve analysis, sST2 predicted ICU admission, ventilator use, ECMO use, and 30-day mortality comparable to SOFA score but significantly better than critical disease. sST2 predicted ICU admission, ventilator use, and ECMO use significantly better than the 4C mortality score. On Kaplan–Meier survival analysis, hazard ratios (95% confidence interval) were 8.4 (2.7–26.8) for sST2, 14.8 (3.0–71.7) for SOFA score, 1.8 (0.5–6.5) for critical disease, and 11.7 (3.4–40.1) for 4C mortality score. This study demonstrated that sST2 could be a useful biomarker to predict ICU admission, ventilator use, ECMO use, and 30-day mortality in hospitalized COVID-19 patients. sST2 may be implemented as a prognostic COVID-19 biomarker in clinical practice. |
| first_indexed | 2024-03-09T13:03:00Z |
| format | Article |
| id | doaj.art-9d0c337f27d54b5ea6357e4531b87e89 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T13:03:00Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-9d0c337f27d54b5ea6357e4531b87e892023-11-30T21:52:14ZengMDPI AGDiagnostics2075-44182023-01-0113225910.3390/diagnostics13020259Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 PatientsMikyoung Park0Mina Hur1Hanah Kim2Chae Hoon Lee3Jong Ho Lee4Hyung Woo Kim5Minjeong Nam6Seungho Lee7Department of Laboratory Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of KoreaDepartment of Laboratory Medicine, Yeungnam University College of Medicine, Daegu 42415, Republic of KoreaDepartment of Laboratory Medicine, Yeungnam University College of Medicine, Daegu 42415, Republic of KoreaDepartment of Laboratory Medicine, Yeungnam University College of Medicine, Daegu 42415, Republic of KoreaDepartment of Laboratory Medicine, Korea University Anam Hospital, Seoul 02841, Republic of KoreaDepartment of Preventive Medicine, College of Medicine, Dong-A University, Busan 49201, Republic of KoreaSoluble suppression of tumorigenesis-2 (sST2) is an emerging biomarker for sepsis as well as for heart failure. We investigated the prognostic utility of sST2 for predicting clinical outcomes in hospitalized coronavirus disease 2019 (COVID-19) patients. In a total of 52 hospitalized COVID-19 patients, sST2 levels were measured using the ichroma ST2 assay (Boditech Med Inc., Chuncheon-si, Gang-won-do, Republic of Korea). Clinical outcomes included intensive care unit (ICU) admission, ventilator use, extracorporeal membrane oxygenation (ECMO) use, and 30-day mortality. sST2 was analyzed according to clinical outcomes. sST2, sequential organ failure assessment (SOFA) score, critical disease, and 4C mortality score were compared using the receiver operating characteristic (ROC) curve and Kaplan–Meier methods for clinical outcomes. The sST2 level differed significantly according to ICU admission, ventilator use, ECMO use, and 30-day mortality (all <i>p</i> < 0.05). On ROC curve analysis, sST2 predicted ICU admission, ventilator use, ECMO use, and 30-day mortality comparable to SOFA score but significantly better than critical disease. sST2 predicted ICU admission, ventilator use, and ECMO use significantly better than the 4C mortality score. On Kaplan–Meier survival analysis, hazard ratios (95% confidence interval) were 8.4 (2.7–26.8) for sST2, 14.8 (3.0–71.7) for SOFA score, 1.8 (0.5–6.5) for critical disease, and 11.7 (3.4–40.1) for 4C mortality score. This study demonstrated that sST2 could be a useful biomarker to predict ICU admission, ventilator use, ECMO use, and 30-day mortality in hospitalized COVID-19 patients. sST2 may be implemented as a prognostic COVID-19 biomarker in clinical practice.https://www.mdpi.com/2075-4418/13/2/259soluble ST2biomarkerpredictionclinical outcomeCOVID-19 |
| spellingShingle | Mikyoung Park Mina Hur Hanah Kim Chae Hoon Lee Jong Ho Lee Hyung Woo Kim Minjeong Nam Seungho Lee Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients Diagnostics soluble ST2 biomarker prediction clinical outcome COVID-19 |
| title | Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_full | Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_fullStr | Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_full_unstemmed | Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_short | Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_sort | soluble st2 as a useful biomarker for predicting clinical outcomes in hospitalized covid 19 patients |
| topic | soluble ST2 biomarker prediction clinical outcome COVID-19 |
| url | https://www.mdpi.com/2075-4418/13/2/259 |
| work_keys_str_mv | AT mikyoungpark solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients AT minahur solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients AT hanahkim solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients AT chaehoonlee solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients AT jongholee solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients AT hyungwookim solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients AT minjeongnam solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients AT seungholee solublest2asausefulbiomarkerforpredictingclinicaloutcomesinhospitalizedcovid19patients |